AO-176

DRUG2 trials

Sponsors

Arch Oncology

Conditions

Multiple MyelomaSolid Tumor

Phase 1

AO-176 in Multiple Solid Tumor Malignancies

CompletedNCT03834948

Arch OncologySolid Tumor

Start: 2019-02-04End: 2023-02-15Updated: 2023-08-22

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

CompletedNCT04445701

Arch OncologyMultiple Myeloma

Start: 2020-11-30End: 2022-11-14Updated: 2023-08-22

Related Papers

AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms

Blood2021-11-052 citations

260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics

Regular and Young Investigator Award Abstracts2021-11-01

Abstract 954: AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma

Cancer Research2021-07-01

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-2027 citations

Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells

The Journal of Immunology2021-01-1151 citations

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

Blood2020-11-0425 citations

Pre-Clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia

Blood2020-11-043 citations

215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin

Regular and Young Investigator Award Abstracts2020-11-01

Abstract B100: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination antitumor efficacy with chemotherapy and targeted antibodies

Molecular Cancer Therapeutics2019-12-012 citations

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

Blood2019-11-135 citations